F49 - Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infection

Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infection

Download - PDF

Introduction

Epstein-Barr virus (EBV) was discovered in 1964 by electron microscopy of suspension cultures of African Burkitt lymphoma cells (51).

Four years later, EBV was conclusively linked to infectious mononucleosis, which is its most common clinical manifestation (78). The unifying and perplexing characteristic of human herpesviruses, including EBV, is that acquisition results in lifelong infection after the initial viral replication has been contained (172). This review describes advances in the clinical, virologic, and immunologic aspects of primary EBV infection, which have been the focus of our research for the past decade. We discuss the spectrum of clinical illness due to primary EBV infection, risk factors for acquisition and severity of infectious mononucleosis, treatment options for EBV infections, and prospects for a vaccine. Understanding the pathogenesis of EBV infection and applying that knowledge to patient care are of great interest to basic and translational scientists and also to clinicians, especially those in family practice, pediatrics, and internal medicine.

Source:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021204/

gallmet.hu
en_GBEnglish (UK)
Privacy Overview
gallmet.hu

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website collects anonymous information through the use of third-party cookies (Ad-related cookies and Performance cookies)